Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries

Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Newly Diagnosed Multiple Myeloma in Three Gulf Countries

# Background The second most common hematologic cancer worldwide is multiple myeloma (MM), with incidence and mortality rates that have more than doubled over the past 30 years. The safety and efficacy of daratumumab regimens in the treatment of newly diagnosed MM (NDMM) is demonstrated in clinical...

Full description

Saved in:
Bibliographic Details
Main Authors: Anas Hamad, Shereen Elazzazy, Ruba Y. Taha, Hani Osman, Sana Alblooshi, Islam Elkonaissi, Mustaqeem A. Siddiqui, Khalil Al-Farsi, Mohammed Al Lamki, Sali Emara, Gihan H. Elsisi
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2024-07-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.120288
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items